Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
Cipla
Citi
Baxter
Covington
Fish and Richardson
Merck
Accenture

Generated: May 21, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DEXTROMETHORPHAN POLISTIREX

« Back to Dashboard

Clinical Trials for DEXTROMETHORPHAN POLISTIREX

Trial ID Title Status Sponsor Phase Summary
NCT00000352 Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1 Completed University of Pennsylvania Phase 2 The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.
NCT00000352 Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 The purpose of this study is to determine if addition of dextromethorphan to a stable dose of methadone in opioid dependent subjects will significantly affect physical and psychological aspects of opioid tolerance.
NCT00001344 Dextromethorphan Versus Placebo for Neuropathic Pain Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 2 In our current clinical trial, we are comparing the effects of two NMDA receptor antagonists to placebo in patients with painful distal symmetrical diabetic neuropathy or post-herpetic neuralgia. The treatments in this three-period crossover study are dextromethorphan, up to 920 mg/day (about 8 times the antitussive dose), memantine, 30-50 mg/day, and placebo. Memantine is an NMDA antagonist used in Europe to treat Parkinson's disease and Alzheimer's disease. The underlying hypothesis, based on studies of painful neuropathies in animal models, is that neuropathic pain is caused largely by sensitization of central nervous system neurons caused by excitatory amino acid neurotransmitters, acting largely through NMDA receptors. A previous small trial of dextromethorphan suggested efficacy in diabetic neuropathy pain. The study requires one visit to the NIH outpatient Pain Research Clinic, and consists of three 9-week treatment periods. Patients who respond to one of the medications will be invited to participate in further controlled studies of the medication followed by up to several years of open-label treatment under continued observation.
NCT00001365 Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 This study is designed to determine whether dextromethorphan, a drug commonly found in cough medicine, is beneficial and safe for the treatment of Parkinson's disease and other diseases that might share biochemical abnormalities with Parkinson's disease. Patients with Parkinson's disease are missing the chemical neurotransmitter dopamine. This occurs as a result of destructive changes in an area of the brain responsible for making dopamine, the basal ganglia. Rhythmical muscular tremors, rigidity of movement, shuffling footsteps, droopy posture, and a mask-like expression on the face characterize Parkinson's disease. Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinson's Disease.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for DEXTROMETHORPHAN POLISTIREX

Condition Name

Condition Name for DEXTROMETHORPHAN POLISTIREX
Intervention Trials
Healthy 18
Pain 7
Schizophrenia 4
Rett Syndrome 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for DEXTROMETHORPHAN POLISTIREX
Intervention Trials
Alzheimer Disease 7
Neuralgia 6
Syndrome 6
Disease 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for DEXTROMETHORPHAN POLISTIREX

Trials by Country

Trials by Country for DEXTROMETHORPHAN POLISTIREX
Location Trials
United States 294
Canada 9
Brazil 6
Argentina 6
Taiwan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for DEXTROMETHORPHAN POLISTIREX
Location Trials
Maryland 20
Florida 20
California 19
Texas 17
New York 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for DEXTROMETHORPHAN POLISTIREX

Clinical Trial Phase

Clinical Trial Phase for DEXTROMETHORPHAN POLISTIREX
Clinical Trial Phase Trials
Phase 4 18
Phase 3 12
Phase 2/Phase 3 2
[disabled in preview] 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for DEXTROMETHORPHAN POLISTIREX
Clinical Trial Phase Trials
Completed 81
Recruiting 13
Unknown status 8
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for DEXTROMETHORPHAN POLISTIREX

Sponsor Name

Sponsor Name for DEXTROMETHORPHAN POLISTIREX
Sponsor Trials
Avanir Pharmaceuticals 19
Boehringer Ingelheim 6
National Cheng-Kung University Hospital 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for DEXTROMETHORPHAN POLISTIREX
Sponsor Trials
Other 76
Industry 71
NIH 25
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Deloitte
Cerilliant
Teva
Colorcon
Julphar
Cantor Fitzgerald
AstraZeneca
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.